CNTA logo

Centessa Pharmaceuticals (CNTA) EBITDA

annual EBITDA:

-$221.88M-$56.46M(-34.13%)
December 31, 2024

Summary

  • As of today (July 1, 2025), CNTA annual EBITDA is -$221.88 million, with the most recent change of -$56.46 million (-34.13%) on December 31, 2024.
  • CNTA annual EBITDA is now -4394.25% below its all-time high of -$4.94 million, reached on December 31, 2019.

Performance

1-year change

-34.13%

3-year change

-

5-year change

-4394.25%

15-year change

-

CNTA EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

6.8%
CNTA annual EBITDA is higher than 6.8% of companies in Healthcare sector

Range

All-time high

-$4.94M

3-year low

-$221.88M
CNTA annual EBITDA is currently at its 3-year low

Earnings dates

Last annual earnings report date

Dec 31, 2024
CNTA previous annual earnings announcement was published on Dec 31, 2024

Next annual earnings report date

N/A
CNTA next annual earnings announcement has not yet been scheduled

OtherCNTAincome statement metrics

Annual revenue

-
CNTA annual revenue value is unknown

annual net income

-$235.76M
CNTA annual net profit is -$235.76 million

annual EBIT

-$222.82M
CNTA annual earnings before interest & taxes is -$222.82 million

Annual EPS

-$2.06
CNTA annual earnings per share is -$2.06

quarterly EBITDA:

-$21.64M+$85.93M(+79.88%)
March 31, 2025

Summary

  • As of today (July 1, 2025), CNTA quarterly EBITDA is -$21.64 million, with the most recent change of +$85.93 million (+79.88%) on March 31, 2025.
  • Over the past year, CNTA quarterly EBITDA has increased by +$13.15 million (+37.80%).
  • CNTA quarterly EBITDA is now -147.85% below its all-time high of $45.23 million, reached on December 1, 2020.

Performance

3-month change

+79.88%

1-year change

+37.8%

3-year change

+59.08%

5-year change

-147.85%

CNTA quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

21.43%
CNTA quarterly EBITDA is higher than 21.43% of companies in Healthcare sector

Range

All-time high

$45.23M
CNTA quarterly EBITDA is currently -147.85% below its historical high of $45.23 million

3-year low

-$107.57M

Earnings dates

Last quarterly earnings report date

Mar 31, 2025
CNTA previous earnings announcement was published on Mar 31, 2025

Next quarterly earnings report date

Aug 13, 2025
CNTA next earnings announcement is scheduled for Aug 13, 2025

OtherCNTAincome statement metrics

Quarterly revenue

$15.00M
CNTA quarterly revenue is $15.00 million

quarterly net income

-$26.14M
CNTA quarterly net profit is -$26.14 million

quarterly EBIT

-$21.86M
CNTA quarterly earnings before interest & taxes is -$21.86 million

Quarterly EPS

-$0.20
CNTA quarterly earnings per share is -$0.20

TTM EBITDA:

-$208.73M+$13.15M(+5.93%)
March 31, 2025

Summary

  • As of today (July 1, 2025), CNTA TTM EBITDA is -$208.73 million, with the most recent change of +$13.15 million (+5.93%) on March 31, 2025.
  • Over the past year, CNTA TTM EBITDA has dropped by -$56.11 million (-36.77%).
  • CNTA TTM EBITDA is now -348.59% below its all-time high of $83.97 million, reached on March 31, 2021.

Performance

3-month change

+5.93%

1-year change

-36.77%

3-year change

-55.19%

5-year change

-561.44%

CNTA TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

7.74%
CNTA TTM EBITDA is higher than 7.74% of companies in Healthcare sector

Range

All-time high

$83.97M
CNTA TTM EBITDA is currently -348.59% below its historical high of $83.97 million

3-year low

-$221.88M

Earnings dates

Last quarterly earnings report date

Mar 31, 2025
CNTA previous earnings announcement was published on Mar 31, 2025

Next quarterly earnings report date

Aug 13, 2025
CNTA next earnings announcement is scheduled for Aug 13, 2025

OtherCNTAincome statement metrics

TTM revenue

$15.00M
CNTA TTM revenue is $15.00 million

TTM net income

-$223.85M
CNTA TTM net profit is -$223.85 million

TTM EBIT

-$209.65M
CNTA TTM earnings before interest & taxes is -$209.65 million

TTM EPS

-$1.81
CNTA TTM earnings per share is -$1.81

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

annual EBITDA

-$221.88M
CNTA annual EBITDA is -$221.88 million

annual net income

-$235.76M
CNTA annual net profit is -$235.76 million

annual interest expense

$10.09M
CNTA annual interest expense is $10.09 million

annual income tax

$2.84M
CNTA annual income tax is $2.84 million

annual D&A

$942.00K
CNTA annual depreciation & amortization is $942.00 thousand

CNTA EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-34.1%+37.8%-36.8%
3 y3 years-+59.1%-55.2%
5 y5 years-4394.3%-147.8%-561.4%

CNTA EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-34.1%at lowat high+79.9%-42.3%+5.9%
5 y5-year-2057.3%at low-147.8%+79.9%-348.6%+5.9%
alltimeall time-4394.3%at low-147.8%+79.9%-348.6%+5.9%

CNTA EBITDA History

DateAnnualQuarterlyTTM
Mar 2025
-
-$21.64M(-79.9%)
-$208.73M(-5.9%)
Dec 2024
-$221.88M(+34.1%)
-$107.57M(+174.7%)
-$221.88M(+50.7%)
Sep 2024
-
-$39.16M(-2.9%)
-$147.19M(+0.3%)
Jun 2024
-
-$40.35M(+16.0%)
-$146.72M(-3.9%)
Mar 2024
-
-$34.80M(+5.8%)
-$152.62M(-7.7%)
Dec 2023
-$165.43M(-21.1%)
-$32.88M(-15.0%)
-$165.43M(-5.0%)
Sep 2023
-
-$38.70M(-16.3%)
-$174.15M(-7.1%)
Jun 2023
-
-$46.25M(-2.8%)
-$187.51M(-8.2%)
Mar 2023
-
-$47.60M(+14.4%)
-$204.26M(-2.5%)
DateAnnualQuarterlyTTM
Dec 2022
-$209.55M(+1937.4%)
-$41.60M(-20.1%)
-$209.54M(+24.8%)
Sep 2022
-
-$52.06M(-17.4%)
-$167.95M(+7.6%)
Jun 2022
-
-$63.00M(+19.1%)
-$156.04M(+16.0%)
Mar 2022
-
-$52.89M(+31.7%)
-$134.50M(-5799.0%)
Sep 2021
-
-$40.16M(-3.1%)
$2.36M(-94.4%)
Jun 2021
-
-$41.45M(-207.0%)
$42.52M(-49.4%)
Mar 2021
-
$38.73M(-14.4%)
$83.97M(+85.6%)
Dec 2020
-$10.29M(+108.3%)
-
-
Dec 2020
-
$45.23M
$45.23M
Dec 2019
-$4.94M
-
-

FAQ

  • What is Centessa Pharmaceuticals annual EBITDA?
  • What is the all time high annual EBITDA for Centessa Pharmaceuticals?
  • What is Centessa Pharmaceuticals annual EBITDA year-on-year change?
  • What is Centessa Pharmaceuticals quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Centessa Pharmaceuticals?
  • What is Centessa Pharmaceuticals quarterly EBITDA year-on-year change?
  • What is Centessa Pharmaceuticals TTM EBITDA?
  • What is the all time high TTM EBITDA for Centessa Pharmaceuticals?
  • What is Centessa Pharmaceuticals TTM EBITDA year-on-year change?

What is Centessa Pharmaceuticals annual EBITDA?

The current annual EBITDA of CNTA is -$221.88M

What is the all time high annual EBITDA for Centessa Pharmaceuticals?

Centessa Pharmaceuticals all-time high annual EBITDA is -$4.94M

What is Centessa Pharmaceuticals annual EBITDA year-on-year change?

Over the past year, CNTA annual EBITDA has changed by -$56.46M (-34.13%)

What is Centessa Pharmaceuticals quarterly EBITDA?

The current quarterly EBITDA of CNTA is -$21.64M

What is the all time high quarterly EBITDA for Centessa Pharmaceuticals?

Centessa Pharmaceuticals all-time high quarterly EBITDA is $45.23M

What is Centessa Pharmaceuticals quarterly EBITDA year-on-year change?

Over the past year, CNTA quarterly EBITDA has changed by +$13.15M (+37.80%)

What is Centessa Pharmaceuticals TTM EBITDA?

The current TTM EBITDA of CNTA is -$208.73M

What is the all time high TTM EBITDA for Centessa Pharmaceuticals?

Centessa Pharmaceuticals all-time high TTM EBITDA is $83.97M

What is Centessa Pharmaceuticals TTM EBITDA year-on-year change?

Over the past year, CNTA TTM EBITDA has changed by -$56.11M (-36.77%)
On this page